These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34695732)

  • 41. Two pathways for lysophosphatidic acid production.
    Aoki J; Inoue A; Okudaira S
    Biochim Biophys Acta; 2008 Sep; 1781(9):513-8. PubMed ID: 18621144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA
    Sivaraman L; Gill M; Nelson DM; Chadwick KD
    Toxicol Appl Pharmacol; 2022 Mar; 438():115846. PubMed ID: 34974053
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lysophosphatidic acid-induced YAP/TAZ activation promotes developmental angiogenesis by repressing Notch ligand Dll4.
    Yasuda D; Kobayashi D; Akahoshi N; Ohto-Nakanishi T; Yoshioka K; Takuwa Y; Mizuno S; Takahashi S; Ishii S
    J Clin Invest; 2019 Jul; 129(10):4332-4349. PubMed ID: 31335323
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of lysophosphatidic acid in the physiology and pathology of the skin.
    Lei L; Su J; Chen J; Chen W; Chen X; Peng C
    Life Sci; 2019 Mar; 220():194-200. PubMed ID: 30584899
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays.
    Willier S; Butt E; Grunewald TG
    Biol Cell; 2013 Aug; 105(8):317-33. PubMed ID: 23611148
    [TBL] [Abstract][Full Text] [Related]  

  • 46. LPA and its analogs-attractive tools for elucidation of LPA biology and drug development.
    Kano K; Arima N; Ohgami M; Aoki J
    Curr Med Chem; 2008; 15(21):2122-31. PubMed ID: 18781939
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lysophosphatidic acid receptor 1 antagonist ki16425 blunts abdominal and systemic inflammation in a mouse model of peritoneal sepsis.
    Zhao J; Wei J; Weathington N; Jacko AM; Huang H; Tsung A; Zhao Y
    Transl Res; 2015 Jul; 166(1):80-8. PubMed ID: 25701366
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure of the active G
    Akasaka H; Tanaka T; Sano FK; Matsuzaki Y; Shihoya W; Nureki O
    Nat Commun; 2022 Sep; 13(1):5417. PubMed ID: 36109516
    [TBL] [Abstract][Full Text] [Related]  

  • 49. LPA signaling is required for dopaminergic neuron development and is reduced through low expression of the LPA1 receptor in a 6-OHDA lesion model of Parkinson's disease.
    Yang XY; Zhao EY; Zhuang WX; Sun FX; Han HL; Han HR; Lin ZJ; Pan ZF; Qu MH; Zeng XW; Ding Y
    Neurol Sci; 2015 Nov; 36(11):2027-33. PubMed ID: 26169757
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of compounds acting as negative allosteric modulators of the LPA
    Ellery J; Dickson L; Cheung T; Ciuclan L; Bunyard P; Mack S; Buffham WJ; Farnaby W; Mitchell P; Brown D; Isaacs R; Barnes M
    Eur J Pharmacol; 2018 Aug; 833():8-15. PubMed ID: 29807028
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LPA(3), a unique G protein-coupled receptor for lysophosphatidic acid.
    Hama K; Aoki J
    Prog Lipid Res; 2010 Oct; 49(4):335-42. PubMed ID: 20230855
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synaptic enhancement induced by gintonin via lysophosphatidic acid receptor activation in central synapses.
    Park H; Kim S; Rhee J; Kim HJ; Han JS; Nah SY; Chung C
    J Neurophysiol; 2015 Mar; 113(5):1493-500. PubMed ID: 25505112
    [TBL] [Abstract][Full Text] [Related]  

  • 53. LPA
    Dancs PT; Ruisanchez É; Balogh A; Panta CR; Miklós Z; Nüsing RM; Aoki J; Chun J; Offermanns S; Tigyi G; Benyó Z
    FASEB J; 2017 Apr; 31(4):1547-1555. PubMed ID: 28069828
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA
    Cheng PTW; Kaltenbach RF; Zhang H; Shi J; Tao S; Li J; Kennedy LJ; Walker SJ; Shi Y; Wang Y; Dhanusu S; Reddigunta R; Kumaravel S; Jusuf S; Smith D; Krishnananthan S; Li J; Wang T; Heiry R; Sum CS; Kalinowski SS; Hung CP; Chu CH; Azzara AV; Ziegler M; Burns L; Zinker BA; Boehm S; Taylor J; Sapuppo J; Mosure K; Everlof G; Guarino V; Zhang L; Yang Y; Ruan Q; Xu C; Apedo A; Traeger SC; Cvijic ME; Lentz KA; Tirucherai G; Sivaraman L; Robl J; Ellsworth BA; Rosen G; Gordon DA; Soars MG; Gill M; Murphy BJ
    J Med Chem; 2021 Nov; 64(21):15549-15581. PubMed ID: 34709814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Production of extracellular lysophosphatidic acid in the regulation of adipocyte functions and liver fibrosis.
    Yang F; Chen GX
    World J Gastroenterol; 2018 Sep; 24(36):4132-4151. PubMed ID: 30271079
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.
    Ohashi T; Yamamoto T
    Exp Dermatol; 2015 Sep; 24(9):698-702. PubMed ID: 25959255
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Strategy for the identification of GPR23/LPA4 receptor agonists and inverse agonists.
    Wong SH; Mallari R; Graham M; Atangan L; Lu SC; Zhao X; Gu W; Lee PH
    Assay Drug Dev Technol; 2010 Aug; 8(4):459-70. PubMed ID: 20482379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diverse effects of LPA receptors on cell motile activities of cancer cells.
    Tsujiuchi T; Hirane M; Dong Y; Fukushima N
    J Recept Signal Transduct Res; 2014 Jun; 34(3):149-53. PubMed ID: 24460191
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis.
    David M; Ribeiro J; Descotes F; Serre CM; Barbier M; Murone M; Clézardin P; Peyruchaud O
    Int J Oncol; 2012 Apr; 40(4):1133-41. PubMed ID: 22200658
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.
    Ohta H; Sato K; Murata N; Damirin A; Malchinkhuu E; Kon J; Kimura T; Tobo M; Yamazaki Y; Watanabe T; Yagi M; Sato M; Suzuki R; Murooka H; Sakai T; Nishitoba T; Im DS; Nochi H; Tamoto K; Tomura H; Okajima F
    Mol Pharmacol; 2003 Oct; 64(4):994-1005. PubMed ID: 14500756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.